Human-Relevant Discovery Begins With the Model: A Conversation With Shushant Jain

When early discovery teams debate how to make better decisions, they tend to focus on new modalities, faster analytics or incremental workflow improvements. But for Shushant Jain, Director of Ncardia’s drug discovery technology group, the real leverage sits deeper: in the design of the model itself. If the biology is misaligned with the question, no amount of downstream optimization can recover meaningful insight.